Trinity Biotech (TRIB) Competitors $0.69 +0.02 (+2.81%) As of 03/21/2025 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends TRIB vs. OTLK, ALVR, ITRM, RPTX, IBIO, IMMX, NBRV, CNTB, FGEN, and ICCCShould you be buying Trinity Biotech stock or one of its competitors? The main competitors of Trinity Biotech include Outlook Therapeutics (OTLK), AlloVir (ALVR), Iterum Therapeutics (ITRM), Repare Therapeutics (RPTX), iBio (IBIO), Immix Biopharma (IMMX), Nabriva Therapeutics (NBRV), Connect Biopharma (CNTB), FibroGen (FGEN), and ImmuCell (ICCC). These companies are all part of the "pharmaceutical products" industry. Trinity Biotech vs. Outlook Therapeutics AlloVir Iterum Therapeutics Repare Therapeutics iBio Immix Biopharma Nabriva Therapeutics Connect Biopharma FibroGen ImmuCell Outlook Therapeutics (NASDAQ:OTLK) and Trinity Biotech (NASDAQ:TRIB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, community ranking, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership. Does the MarketBeat Community favor OTLK or TRIB? Trinity Biotech received 170 more outperform votes than Outlook Therapeutics when rated by MarketBeat users. However, 71.12% of users gave Outlook Therapeutics an outperform vote while only 70.97% of users gave Trinity Biotech an outperform vote. CompanyUnderperformOutperformOutlook TherapeuticsOutperform Votes16571.12% Underperform Votes6728.88% Trinity BiotechOutperform Votes33570.97% Underperform Votes13729.03% Do institutionals and insiders hold more shares of OTLK or TRIB? 11.2% of Outlook Therapeutics shares are owned by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are owned by institutional investors. 4.8% of Outlook Therapeutics shares are owned by insiders. Comparatively, 8.2% of Trinity Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is OTLK or TRIB more profitable? Outlook Therapeutics has a net margin of 0.00% compared to Trinity Biotech's net margin of -34.39%. Company Net Margins Return on Equity Return on Assets Outlook TherapeuticsN/A N/A -225.12% Trinity Biotech -34.39%N/A -21.37% Which has more volatility & risk, OTLK or TRIB? Outlook Therapeutics has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Comparatively, Trinity Biotech has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Which has better earnings and valuation, OTLK or TRIB? Trinity Biotech has higher revenue and earnings than Outlook Therapeutics. Trinity Biotech is trading at a lower price-to-earnings ratio than Outlook Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOutlook TherapeuticsN/AN/A-$75.37M-$7.42-0.20Trinity Biotech$59.13M0.21-$24.02M-$2.26-0.31 Does the media refer more to OTLK or TRIB? In the previous week, Outlook Therapeutics had 1 more articles in the media than Trinity Biotech. MarketBeat recorded 3 mentions for Outlook Therapeutics and 2 mentions for Trinity Biotech. Trinity Biotech's average media sentiment score of 0.50 beat Outlook Therapeutics' score of 0.23 indicating that Trinity Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Outlook Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Trinity Biotech 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend OTLK or TRIB? Outlook Therapeutics presently has a consensus price target of $10.20, suggesting a potential upside of 575.50%. Given Outlook Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Outlook Therapeutics is more favorable than Trinity Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Outlook Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Trinity Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryTrinity Biotech beats Outlook Therapeutics on 9 of the 16 factors compared between the two stocks. Remove Ads Get Trinity Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for TRIB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRIB vs. The Competition Export to ExcelMetricTrinity BiotechDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.19M$2.47B$5.72B$8.14BDividend YieldN/A0.70%4.41%4.07%P/E Ratio-0.315.5724.3618.98Price / Sales0.2153.28398.3491.58Price / CashN/A15.7538.1634.64Price / Book-0.223.107.104.43Net Income-$24.02M-$65.73M$3.20B$247.36M7 Day Performance1.30%0.19%1.95%1.94%1 Month Performance-9.68%-9.08%3.53%-6.13%1 Year Performance-67.26%-16.98%14.27%3.61% Trinity Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRIBTrinity Biotech1.4698 of 5 stars$0.69+2.8%N/A-67.7%$12.19M$59.13M-0.31480Analyst ForecastNews CoverageOTLKOutlook Therapeutics1.6743 of 5 stars$1.54-1.9%$10.20+562.3%-78.6%$49.31MN/A-0.2120News CoverageALVRAlloVir2.7485 of 5 stars$9.66+0.1%N/A-35.7%$48.72MN/A-0.48110Positive NewsGap DownITRMIterum Therapeutics2.461 of 5 stars$1.40+1.4%$5.00+257.1%-8.9%$48.41MN/A-1.0710Short Interest ↓News CoveragePositive NewsRPTXRepare Therapeutics3.0419 of 5 stars$1.14+3.2%$4.50+296.5%-78.5%$48.25M$53.48M-0.57180IBIOiBio0.3286 of 5 stars$4.86-4.3%$4.30-11.5%N/A$47.99M$375,000.000.00100Analyst UpgradeIMMXImmix Biopharma2.1632 of 5 stars$1.73+4.8%$7.00+304.6%-40.8%$47.59MN/A-2.049Upcoming EarningsNews CoveragePositive NewsNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070Analyst ForecastNews CoverageGap DownCNTBConnect Biopharma2.2756 of 5 stars$0.82-4.0%$8.00+873.2%-33.9%$45.42M$24.12M0.00110Gap DownFGENFibroGen3.9474 of 5 stars$0.45+1.3%$10.00+2,147.2%-87.0%$44.84M$180.02M-0.36570Earnings ReportAnalyst ForecastAnalyst RevisionICCCImmuCellN/A$4.97-0.4%N/A-3.5%$44.29M$26.49M-9.9470 Remove Ads Related Companies and Tools Related Companies Outlook Therapeutics Competitors AlloVir Competitors Iterum Therapeutics Competitors Repare Therapeutics Competitors iBio Competitors Immix Biopharma Competitors Nabriva Therapeutics Competitors Connect Biopharma Competitors FibroGen Competitors ImmuCell Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRIB) was last updated on 3/22/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trinity Biotech plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Trinity Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
